Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
about
Gene Therapy Applications to Cancer TreatmentImmunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesGlycotherapy: new advances inspire a reemergence of glycans in medicineDeciphering Structural Elements of Mucin Glycoprotein RecognitionA novel Gal(beta1-4)Gal(beta1-4)Fuc(alpha1-6)-core modification attached to the proximal N-acetylglucosamine of keyhole limpet haemocyanin (KLH) N-glycans.Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.Current status of mucins in the diagnosis and therapy of cancer.Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against breast tumor associated antigen.Recent advances in the development of breast cancer vaccines.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Proteomic comparison of mcf-7 tumoursphere and monolayer culturesCarbohydrate-based vaccines with a glycolipid adjuvant for breast cancerControlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumabImmunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trialAlpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer.Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activityConstruction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresolMucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).Tumor vaccines for breast cancerTumor-associated antigens in breast cancer.MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterpartsNatural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Single-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis.Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.Natural and Induced Humoral Responses to MUC1.A versatile bifunctional dendritic cell targeting vaccine vectorCarrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy.Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model.Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity.Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer.
P2860
Q24792808-602C5D23-5E81-4202-B608-D7FE3861A628Q26740513-47E9D81D-8518-4E1B-94E8-311020A724FAQ27027997-1BE824FA-08E8-430D-AE37-5917AE393A34Q27678183-9FD57A10-8F0D-4979-93B3-F4F6D0505069Q31024258-C7F01C6E-81C8-4391-BB40-B07064844B2BQ31047715-74E07D37-C65C-46CF-A23F-C523AD0BF8F0Q33470026-687E5CBB-FBD2-4E9A-AC83-2EC79BC4DD06Q33757326-BD592D2D-788E-4EAE-85BD-EA8DA56D8D89Q34111694-2D136FB4-9521-4343-90A6-039E297C49D1Q34379303-0F077389-4F77-45F2-A858-4216854F3AF9Q34494018-2D2AF214-A09C-4997-89EA-D53BE7AFF6AEQ34534423-3CBDBE1B-9A08-4A55-8D8E-A1CDEF4CF337Q34565029-2C084E82-4AC5-4991-9AC5-5455223CCE0AQ34621713-49DE3135-04FF-4399-867E-73149B5759B7Q34720308-F1C53CCA-97C5-493C-9A7D-C54E81ED6D48Q34771278-C137327D-ACB0-4E93-8063-25B0017B5573Q34782050-A016FC35-E754-4668-9587-4A0E4B46AD3BQ35106317-BC115B1F-5A29-46CE-9079-434B6CB75E65Q35539051-5F0DE539-9DED-480B-9221-D0C3F6C5B0A2Q35591546-638DFBFF-6C9D-4EB5-8A77-39FC495A321DQ35657628-C12D0151-CB89-4D4E-981D-48269B197E41Q35934485-408D45EB-AC15-47C1-8202-1C8584D4A061Q36204803-E4E245F1-09E1-4A6C-8F94-A683122A0DFFQ36449259-F56DDE2A-03F3-4BE6-B145-E3F41C7F30B9Q36508191-243257D5-65B1-44A2-8B1C-FB96FBE4F047Q36604334-C8CDEC7F-AE8D-4D88-BC1F-D00A523BCD98Q36648430-0B166BB1-9111-4CA0-9B48-6FD98E3436C3Q36653524-F65E8366-E788-4C0E-BBEF-94F0D224A830Q36746712-C75840CF-D643-427B-99DA-A3765F0AE373Q36856279-B4619A72-1AD0-4065-BC7B-FD8D124F3937Q36901719-60B4BF97-621E-415E-B3B3-B0EC5306F244Q36915898-B8029926-FC9A-4398-9605-0FEB285A3C9FQ37011520-6F76582B-B37F-4080-A2A4-000679A1CB9DQ37137385-84EE8DE0-37A4-4D50-9394-C32A40EF3CC9Q37183994-D39CBF52-1089-4CFC-8CD7-BFBE54F3FA1FQ37660270-F6FFC8B2-C663-439C-AF15-BDF8CFDE793BQ39658273-5D3D92F1-47E3-44DC-9074-A37D19CC22B9Q41828763-79691407-9E52-42EC-964F-84472E72EAF8Q41936513-576128CD-2164-4BC1-84D9-F59E6906A68EQ47097183-1ADA19FC-B399-4ECB-AEA5-4F438854E5D8
P2860
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Vaccination of high-risk breas ...... mocyanin conjugate plus QS-21.
@en
type
label
Vaccination of high-risk breas ...... mocyanin conjugate plus QS-21.
@en
prefLabel
Vaccination of high-risk breas ...... mocyanin conjugate plus QS-21.
@en
P2093
P1476
Vaccination of high-risk breas ...... mocyanin conjugate plus QS-21.
@en
P2093
A Houghton
G Ragupathi
K Panageas
M Moynahan
P O Livingston
T Gilewski
P304
P407
P50
P577
2000-05-01T00:00:00Z